Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2000 May 15;191(10):1699–1708. doi: 10.1084/jem.191.10.1699

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2000 The Rockefeller University Press

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Retroviral transduction of DCs enhances their efficacy as therapeutic tumor vaccines. (A) FACS^® profile of DCs transduced with the retrovirus CMMP-GFP. The fluorescence is compared with nontransduced DCs. (B) Mice with preexisting B16-MAGE-1 tumors (n = 5/group) were immunized on day 5 after tumor inoculation with 10⁶ DC subcutaneously. Error bars represent the SE of the mean. (C–E) Kaplan-Meier survival graphs showing long-term tumor-free survival. Groups of 10 mice were treated with a single dose of 10⁶ DCs (in E, 1 group received 3 injections in weekly intervals) or irradiated cytokine-transduced tumor cell vaccines (10⁶) 5 d after subcutaneous injection of 5 × 10⁵ B16-MAGE-1 tumor cells. P values are determined by statistical comparison against the survival of mice treated with DC-Ad-MAGE-1 cells.

Retroviral transduction of DCs enhances their efficacy as therapeutic tumor vaccines. (A) FACS^® profile of DCs transduced with the retrovirus CMMP-GFP. The fluorescence is compared with nontransduced DCs. (B) Mice with preexisting B16-MAGE-1 tumors (n = 5/group) were immunized on day 5 after tumor inoculation with 10⁶ DC subcutaneously. Error bars represent the SE of the mean. (C–E) Kaplan-Meier survival graphs showing long-term tumor-free survival. Groups of 10 mice were treated with a single dose of 10⁶ DCs (in E, 1 group received 3 injections in weekly intervals) or irradiated cytokine-transduced tumor cell vaccines (10⁶) 5 d after subcutaneous injection of 5 × 10⁵ B16-MAGE-1 tumor cells. P values are determined by statistical comparison against the survival of mice treated with DC-Ad-MAGE-1 cells.